# Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients

> **NCT02456012** · PHASE4 · COMPLETED · sponsor: **Hsiu-Chi Cheng** · enrollment: 268 (actual)

## Conditions studied

- Peptic Ulcer Hemorrhage

## Interventions

- **DRUG:** oral esomeprazole 20 mg twice daily
- **DRUG:** oral esomeprazole 20 mg once daily

## Key facts

- **NCT ID:** NCT02456012
- **Lead sponsor:** Hsiu-Chi Cheng
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04
- **Primary completion:** 2020-12-31
- **Final completion:** 2020-12-31
- **Target enrollment:** 268 (ACTUAL)
- **Last updated:** 2022-02-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02456012

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02456012, "Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02456012. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*